CA
GILD icon

Capitolis Advisors’s Gilead Sciences GILD Stock Holding History

Capitolis Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57,393
Closed -$4.17M – 286
2021
Q4 		$4.17M Buy
57,393
+15,854
+38% +$1.09M 0.02% 332
2021
Q3 		$2.74M Buy
41,539
+38,166
+1,132% +$2.68M 0.02% 272
2021
Q2 		$232K Sell
3,373
-69,671
-95% -$4.65M ﹤0.01% 373
2021
Q1 		$4.72M Hold
73,044
– – 0.08% 175
2020
Q4 		$4.26M Buy
+73,044
New +$4.41M 0.07% 219

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capitolis Advisors's GILD Position: Q1 2022 in Review

Capitolis Advisors sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 57,393 shares — an estimated $4.17M sold.

Capitolis Advisors first reported a position in GILD in Q4 2020 and held it in 5 quarters. The position peaked at $4.72M in Q1 2021. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

  • Capitolis Advisors reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 57,393 Gilead Sciences shares in Q1 2022, an estimated $4.17M.
  • Capitolis Advisors first reported a position in Gilead Sciences in Q4 2020 and held it in 5 quarters.
  • Capitolis Advisors's Gilead Sciences position peaked at $4.72M in Q1 2021.
  • 1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.